Study finds hope for oral hepatitis C regimen

01/19/2012 | Bloomberg

A study published in the New England Journal of Medicine found that 36% of hepatitis C patients who took the oral drug candidates daclatasvir and asunaprevir had undetectable viral loads after 24 weeks. Meanwhile, nine in 10 patients responded to the combination plus ribavirin and interferon. This is the first study to indicate that difficult-to-treat cases might respond without the aid of injectable interferon, said the lead researcher.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC
Director, Health Services Analytics
Avalere Health
Washington, DC
Director/Vice President. Health Actuary
Avalere Health
Washington, DC
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD